Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Spineart and eCential Robotics Secure FDA 510(k) Clearance for PERLA® TL Robotic Application: Spineart and eCential Robotics received FDA 510(k) clearance for the PERLA® TL application, integrating Spineart's thoracolumbar pedicle screw system directly with eCential's Op.n open robotic navigation platform.
• FDA Grants Breakthrough Device Designation for Avalanche Medical's SyCap™ Knee Resurfacing Implant: Avalanche Medical was granted FDA Breakthrough Device Designation for its SyCap™ non-degradable polymer implant, engineered for focal joint-preserving resurfacing of knee osteochondral defects.
• GMReis Obtains FDA 510(k) Clearance for STITCH High-Strength Orthopaedic Sutures: GMReis secured FDA clearance for its STITCH portfolio of ultra-high-molecular-weight polyethylene (UHMWPE) non-absorbable sutures and braided sleeves for sports medicine tendon and ligament reconstruction.

DAILY ANNOUNCEMENTS BY CATEGORY

Surgical Robotics, AI & Navigation

Spineart & eCential Robotics — FDA 510(k) Clearance for PERLA® TL Application on Op.n Robotic Navigation System

• Summary: Spineart and eCential Robotics announced that the FDA has granted 510(k) clearance for the PERLA® TL software application. This milestone enables Spineart's PERLA® thoracolumbar pedicle screw portfolio to operate seamlessly with the eCential Op.n open navigation and robotic-assisted spine surgical platform. The integration delivers unified, real-time 3D navigation and robotic guidance for planning and executing pedicle screw placement in degenerative, deformity, and trauma thoracolumbar fusions.
• Key Details:
  • Device/System Name: PERLA® TL Application & eCential Op.n Robotic Navigation System
  • Status: FDA 510(k) Cleared (August 26, 2026)
  • Clinical Significance: Combines robotic trajectory accuracy with premium thoracolumbar instrumentation, reducing screw malpositioning risks, surgical revision rates, and intraoperative radiation exposure.
• Original Source: Spineart & eCential Robotics FDA Clearance Announcement — OrthoSpineNews

Joint Reconstruction & Cartilage Restoration

Avalanche Medical — FDA Breakthrough Device Designation for SyCap™ Focal Knee Resurfacing Implant

• Summary: Avalanche Medical announced that its SyCap™ non-degradable synthetic cartilage resurfacing implant has received Breakthrough Device Designation from the US FDA. Engineered from a proprietary biocompatible polymer designed to match the biphasic tribological and compressive properties of native articular cartilage, SyCap provides focal joint resurfacing for full-thickness femoral and trochlear osteochondral defects in patients too young or active for total knee arthroplasty.
• Key Details:
  • Device/System Name: SyCap™ Non-Degradable Focal Knee Resurfacing Implant
  • Status: FDA Breakthrough Device Designation (August 26, 2026)
  • Clinical Significance: Provides an off-the-shelf, load-bearing joint preservation option for symptomatic focal cartilage defects, delaying or eliminating the need for early knee arthroplasty.
• Original Source: Avalanche Medical Breakthrough Device Update — Orthoworld

Sports Medicine & Soft Tissue Reconstruction

GMReis — Receives FDA 510(k) Clearance for STITCH UHMWPE High-Strength Surgical Sutures

• Summary: GMReis obtained FDA 510(k) clearance for its STITCH portfolio of ultra-high-molecular-weight polyethylene (UHMWPE) non-absorbable surgical sutures and braided sleeves. Specifically developed for sports medicine, extremity reconstruction, and tendon-to-bone reattachment, STITCH provides high tensile strength, knot security, and reduced tissue abrasion for integration with suture anchors and flexible orthopaedic fixation systems.
• Key Details:
  • Device/System Name: STITCH™ UHMWPE Surgical Suture & Braided Sleeve System
  • Status: FDA 510(k) Cleared (August 25–26, 2026)
  • Clinical Significance: Enhances mechanical fixation strength in rotator cuff repair, labral reconstruction, and ligamentous reattachment, reducing elongation and anchor pullout risks under high athletic loads.
• Original Source: GMReis FDA 510(k) Clearance Report — Orthoworld

Spine Health Policy & Reimbursement

DeGen Medical — Statement on CMS FY2027 Inpatient Classification for Patient-Specific Lumbar Fusion

• Summary: DeGen Medical released an industry statement addressing the finalized CMS Inpatient Prospective Payment System (IPPS) classifications for fiscal year 2027. The updated coding frameworks establish explicit reimbursement pathways for patient-specific, 3D-printed titanium implants used in complex adult spinal deformity and revision fusion, providing financial predictability for hospital adoption of personalized spinal implants.
• Key Details:
  • Device/System Name: Patient-Specific 3D-Printed Titanium Lumbar Implants
  • Status: Regulatory & Health Policy Review
  • Clinical Significance: Removes hospital reimbursement barriers for custom 3D-printed interbody and fixation constructs, expanding patient access in complex reconstructive spine cases.
• Original Source: DeGen Medical CMS Policy Statement — OrthoSpineNews

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)